Fig. 2
Development and validation of the migrasome-related lncRNA prognostic signature (A). PCA analysis of CRC patients based on the whole expression profiles and selected migrasome-related lncRNAs; (B and C). The Kaplan–Meier analysis of overall survival for patients with high risk scores and low risk scores in the training and testing sets; (D). The Kaplan–Meier analysis of progression-free survival for patients with high risk scores and low risk scores; (E). The risk score distribution map and the expression profiles of 10 prognostic migrasome-related lncRNAs among high-risk and low-risk patients; (F). The survival-related ROC curve analysis of patients based on the migrasome-related signature.
